Merck Navigates Acquisition Impact.
Merck's Q2 Net Loss Driven by Terns Acquisition, But Sales Rise and New Drugs Gain Traction.
Anonymous
Key Points
1
Terns acquisition-related charges total about $2.43 per share for 2026, comprised of a $2.31 per-share one-time charge plus roughly $0.12 per share in financing costs to fund the deal and advance MK-4208.
2
Winrevair beat expectations with second-quarter sales of about $588 million, up roughly 75% year over year as a notable contributor to Merck’s growth beyond Keytruda.
3
Keytruda remains a major driver, with the drug generating about $8.4 billion in sales in Q2, and a new form called Qlex contributing about $463 million to those sales.
4
The deal with Terns closed in May, underscoring the timing of the acquisitions-related costs and the push to build a broader pipeline ahead of Keytruda’s patent expiration.
5
Merck’s stock moved modestly higher in pre-market trading, with shares up about 1.28% to roughly $129.45 ahead of the regular session.
Merck posted a Q2 2026 GAAP net loss of about $1.3 billion, but that figure masked a strong underlying quarter. Adjusted earnings came in at a loss of just $0.13 per share — far better than the analyst estimate of a $1.27 loss, according to Yahoo Finance. Revenue rose roughly 5% to about $16.6 billion, driven by blockbuster cancer drug Keytruda and a surging newcomer called Winrevair.
The headline loss was almost entirely due to a $2.31-per-share charge tied to Merck's acquisition of Terns Pharmaceuticals, which closed in May. Merck trimmed its full-year adjusted EPS guidance to $2.66–$2.76 and tightened its sales outlook to $66.3–$67.3 billion. Shares climbed about 1.28% in pre-market trading to roughly $129.45, signaling a cautiously positive reception from investors.
Keytruda and Winrevair Power Revenue Growth
Keytruda remained Merck's biggest engine, generating about $8.4 billion in Q2 sales alone. A new injectable form of the drug, called Qlex, added roughly $463 million to that total. Keytruda is a cancer immunotherapy drug that works by helping the immune system attack tumors. It now accounts for more than half of Merck's quarterly revenue.
Winrevair, a drug for pulmonary arterial hypertension — a condition that raises blood pressure in the lungs — delivered a standout quarter. Sales hit about $588 million, up roughly 75% year over year, according to Yahoo Finance. That growth beat analyst expectations and underscored Merck's push to build revenue streams beyond Keytruda.
Terns Acquisition Drives the Big One-Time Loss
The Terns Pharmaceuticals deal, which closed in May, is the main reason Merck reported a net loss this quarter. The acquisition triggered a one-time charge of $2.31 per share. On top of that, financing costs to fund the deal and advance a drug called MK-4208 added about $0.12 per share. Together, the Terns-related charges total roughly $2.43 per share for 2026.
MK-4208 is an oral drug candidate aimed at treating fatty liver disease, a large and fast-growing market. Merck is betting this pipeline asset, gained through Terns, can become a major product. The timing of the deal means its costs are front-loaded into 2026 results, pressuring adjusted margins for the year.
Merck Races to Build a Life After Keytruda
Keytruda's core patents begin expiring later this decade, which puts enormous pressure on Merck to find new revenue. The company's strategy is clear: acquire promising drugs and launch new products now, while Keytruda cash flow remains strong. Winrevair and Qlex are early proof points of that plan working, according to Yahoo Finance.
Merck also raised the top end of its sales forecast, with some mid-year assessments pointing to an upper target near $66.8 billion, according to MedWatch. The tightened guidance range signals management's growing confidence in the second half of the year. Still, adjusted margins remain under pressure as the company absorbs the costs of its growth push.
Investors React: A Beat That Cuts Through the Noise
On paper, a net loss of $1.3 billion looks alarming. But Wall Street saw through the one-time charges quickly. The adjusted loss of $0.13 per share crushed the consensus estimate of a $1.27 loss — a massive beat by any measure, according to Yahoo Finance. Shares responded with a modest pre-market gain of about 1.28%, pushing the stock to around $129.45.
The market's read is that Merck's core business is healthy. Keytruda keeps growing. Winrevair is outperforming. And the Terns costs, while large, are temporary and strategic. The question investors will watch is whether new launches can fill enough of the gap when Keytruda's patent protection fades later this decade.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
22
Articles
54
Reach
76
A
AnonymousAuthor
